{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:33:24Z","timestamp":1791477204895,"version":"4.3.4"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.pharmthera.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T05:00:14Z","timestamp":1483074014000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?"],"prefix":"10.1016","volume":"169","author":[{"given":"Deborah L.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne A.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Sleeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0005","doi-asserted-by":"crossref","first-page":"L193","DOI":"10.1152\/ajplung.2000.278.1.L193","article-title":"Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2","volume":"278","author":"Akers","year":"2000","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGFbeta signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0015","first-page":"1657","article-title":"Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo","volume":"63","author":"Akiri","year":"2003","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1165\/ajrcmb.21.6.3719","article-title":"Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis","volume":"21","author":"Allen","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9643","key":"10.1016\/j.pharmthera.2016.09.010_bb0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet (Lond Engl)"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol Pathol"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2016.09.010_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1242\/jcs.00229","article-title":"Making sense of latent TGFbeta activation","volume":"116","author":"Annes","year":"2003","journal-title":"J Cell Sci"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0040","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3892\/or.2013.2753","article-title":"Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer","volume":"30","author":"Antoniou","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.tim.2016.06.008","article-title":"Emerging Technologies for Gut Microbiome Research","author":"Arnold","year":"2016","journal-title":"Trends Microbiol"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.09.010_bb0050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1164\/rccm.201502-0299OC","article-title":"Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis","volume":"193","author":"Bardou","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0055","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1165\/rcmb.2013-0310OC","article-title":"A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis","volume":"52","author":"Bauer","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.48.7.736","article-title":"Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis","volume":"48","author":"Behr","year":"1993","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1165\/rcmb.2002-0009OC","article-title":"Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis","volume":"27","author":"Belperio","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/ajrccm.157.1.9704130","article-title":"Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis","volume":"157","author":"Bjoraker","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0080","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1096\/fj.201500197R","article-title":"Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis","volume":"30","author":"Black","year":"2016","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0090","first-page":"286","article-title":"Eosinophils in asthma","volume":"68","author":"Busse","year":"1992","journal-title":"Ann Allergy"},{"issue":"5573","key":"10.1016\/j.pharmthera.2016.09.010_bb0095","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Sci (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/1755-1536-6-20","article-title":"Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes","volume":"6","author":"Clarke","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0105","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.pharmthera.2016.09.010_bb0110","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0120","first-page":"301","article-title":"Fibroblasts and myofibroblasts in wound healing","volume":"7","author":"Darby","year":"2014","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0125","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.4049\/jimmunol.179.9.6043","article-title":"TGF-beta1 induces progressive pleural scarring and subpleural fibrosis","volume":"179","author":"Decologne","year":"2007","journal-title":"J Immunol"},{"issue":"21","key":"10.1016\/j.pharmthera.2016.09.010_bb0130","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2013-204596","article-title":"Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis","volume":"70","author":"Depianto","year":"2015","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PloS one"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","article-title":"Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis","volume":"184","author":"Du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063432","article-title":"Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology","volume":"8","author":"Egger","year":"2013","journal-title":"PloS one"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0155","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.09.010_bb0165","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.183.1.195","article-title":"Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model","volume":"183","author":"Foster","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.08.003","article-title":"B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis","volume":"56","author":"Francois","year":"2015","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/01926230701198469","article-title":"Inhibition of ALK5 signaling induces physeal dysplasia in rats","volume":"35","author":"Frazier","year":"2007","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0480-7","article-title":"The future of the development of medicines in idiopathic pulmonary fibrosis","volume":"13","author":"Fregonese","year":"2015","journal-title":"BMC medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1242\/dmm.012062","article-title":"Diverse functions of matrix metalloproteinases during fibrosis","volume":"7","author":"Giannandrea","year":"2014","journal-title":"Dis Model Mech"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008959","article-title":"CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis","volume":"5","author":"Gilani","year":"2010","journal-title":"PloS one"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1378\/chest.15-1511","article-title":"Molecular endotyping of pulmonary fibrosis","volume":"149","author":"Goodwin","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nri978","article-title":"Alternative activation of macrophages","volume":"3","author":"Gordon","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0210","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.rmed.2008.11.001","article-title":"Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis","volume":"103","author":"Gribbin","year":"2009","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.pharmthera.2016.09.010_bb0215","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrd3297","article-title":"Targeting non-malignant disorders with tyrosine kinase inhibitors","volume":"9","author":"Grimminger","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0220","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0225","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1164\/ajrccm.160.3.9806029","article-title":"Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness","volume":"160","author":"Hamelmann","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0230","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1073\/pnas.1315854111","article-title":"IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis","volume":"111","author":"Hams","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.09.010_bb0235","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0240","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1165\/ajrcmb.18.1.2627","article-title":"Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung","volume":"18","author":"Hancock","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0245","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000071783","article-title":"Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma","volume":"207","author":"Hasegawa","year":"2003","journal-title":"Dermatol (Basel, Switz)"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0255","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am J Pathol"},{"issue":"13","key":"10.1016\/j.pharmthera.2016.09.010_bb0260","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0265","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1183\/09031936.02.00022302","article-title":"Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF","volume":"20","author":"Henry","year":"2002","journal-title":"Eur Respir J"},{"issue":"205","key":"10.1016\/j.pharmthera.2016.09.010_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005964","article-title":"Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis","volume":"5","author":"Herazo-Maya","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","article-title":"Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation","volume":"177","author":"Horan","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0280","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.matbio.2015.02.002","article-title":"Matrix metalloproteinases in destructive lung disease","volume":"44-46","author":"Houghton","year":"2015","journal-title":"Matrix Biol."},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0290","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0002-9440(10)62354-1","article-title":"Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis","volume":"166","author":"Howell","year":"2005","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0295","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1165\/rcmb.2013-0070OC","article-title":"Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice","volume":"49","author":"Huang","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8997","key":"10.1016\/j.pharmthera.2016.09.010_bb0300","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0140-6736(96)90465-1","article-title":"Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis","volume":"347","author":"Hubbard","year":"1996","journal-title":"Lancet (Lond Engl)"},{"issue":"5691","key":"10.1016\/j.pharmthera.2016.09.010_bb0305","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1100283","article-title":"A critical role for eosinophils in allergic airways remodeling","volume":"305","author":"Humbles","year":"2004","journal-title":"Sci (New York, N.Y.)"},{"issue":"22","key":"10.1016\/j.pharmthera.2016.09.010_bb0310","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pharmthera.2016.09.010_bb0315","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0320","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0325","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1164\/rccm.201510-2032PP","article-title":"Roles of periostin in respiratory disorders","volume":"193","author":"Izuhara","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0330","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1385\/IR:30:3:339","article-title":"Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis","volume":"30","author":"Jakubzick","year":"2004","journal-title":"Immunol Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0335","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0340","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1164\/rccm.201203-0506OC","article-title":"Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses","volume":"187","author":"Kahloon","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0345","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1183\/09031936.00040115","article-title":"Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis","volume":"46","author":"Kannengiesser","year":"2015","journal-title":"Eur Respir J"},{"issue":"13","key":"10.1016\/j.pharmthera.2016.09.010_bb0350","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMp1500526","article-title":"Forced vital capacity in idiopathic pulmonary fibrosis\u2014FDA review of pirfenidone and nintedanib","volume":"372","author":"Karimi-Shah","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0355","first-page":"228","article-title":"Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis","volume":"32","author":"Kennedy","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1513\/pats.200601-005TK","article-title":"Classification and natural history of the idiopathic interstitial pneumonias","volume":"3","author":"Kim","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"22","key":"10.1016\/j.pharmthera.2016.09.010_bb0365","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0370","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/ajrccm.164.7.2003140","article-title":"Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0375","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.4049\/jimmunol.172.7.4068","article-title":"Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts","volume":"172","author":"Kolodsick","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0380","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1164\/rccm.200810-1596OC","article-title":"Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis","volume":"180","author":"Konishi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0385","doi-asserted-by":"crossref","first-page":"23034","DOI":"10.1038\/srep23034","article-title":"Sustained PI3K activation exacerbates BLM-induced lung fibrosis via activation of pro-inflammatory and pro-fibrotic pathways","volume":"6","author":"Kral","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0390","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1183\/09031936.00163814","article-title":"The genetic basis of idiopathic pulmonary fibrosis","volume":"45","author":"Kropski","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0395","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1378\/chest.128.3.1475","article-title":"Anticoagulant therapy for idiopathic pulmonary fibrosis","volume":"128","author":"Kubo","year":"2005","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0400","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1164\/ajrccm\/140.6.1693","article-title":"An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis","volume":"140","author":"Kuhn","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0405","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0410","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/pats.200512-137TK","article-title":"The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease?","volume":"3","author":"Lawson","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12079-009-0037-7","article-title":"Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?","volume":"3","author":"Leask","year":"2009","journal-title":"J Cell Commun Signal"},{"issue":"9248","key":"10.1016\/j.pharmthera.2016.09.010_bb0420","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet (Lond Engl)"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0425","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-016-0328-5","article-title":"Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis","volume":"17","author":"Lehtonen","year":"2016","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0430","doi-asserted-by":"crossref","first-page":"L681","DOI":"10.1152\/ajplung.00014.2014","article-title":"Molecular biomarkers in idiopathic pulmonary fibrosis","volume":"307","author":"Ley","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0435","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0440","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0445","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.4049\/jimmunol.173.5.3425","article-title":"Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4\/IL-13 and mediation via STAT-6","volume":"173","author":"Liu","year":"2004","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0450","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/art.30074","article-title":"CCN2 is required for bleomycin-induced skin fibrosis in mice","volume":"63","author":"Liu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0455","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1165\/rcmb.2012-0514OC","article-title":"Telomerase and telomere length in pulmonary fibrosis","volume":"49","author":"Liu","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0460","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1189\/jlb.0707504","article-title":"Roles of T lymphocytes in pulmonary fibrosis","volume":"83","author":"Luzina","year":"2008","journal-title":"J Leukoc Biol"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0465","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0470","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1183\/09031936.00069307","article-title":"Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?","volume":"30","author":"Maher","year":"2007","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0475","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1440-1843.2011.01955.x","article-title":"An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis","volume":"16","author":"Malouf","year":"2011","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0480","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.110.4.1058","article-title":"Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future","volume":"110","author":"Mapel","year":"1996","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0485","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1164\/rccm.200609-1347OC","article-title":"Dendritic cells accumulate in human fibrotic interstitial lung disease","volume":"176","author":"Marchal-Somme","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0490","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.4049\/jimmunol.176.10.5735","article-title":"Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis","volume":"176","author":"Marchal-Somme","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0495","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/thorax.55.2.143","article-title":"Adult familial cryptogenic fibrosing alveolitis in the United Kingdom","volume":"55","author":"Marshall","year":"2000","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.09.010_bb0500","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF","volume":"71","author":"Mercer","year":"2016","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.09.010_bb0505","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1164\/rccm.201403-0541OC","article-title":"The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis","volume":"190","author":"Molyneaux","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0510","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9440(10)62289-4","article-title":"CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury","volume":"166","author":"Moore","year":"2005","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0515","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.200109100","article-title":"The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1","volume":"157","author":"Mu","year":"2002","journal-title":"J Cell Biol"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0520","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.biocel.2008.02.016","article-title":"Hyper-responsiveness of IPF\/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2","volume":"40","author":"Murray","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0525","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biocel.2010.10.013","article-title":"TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P","volume":"43","author":"Murray","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009683","article-title":"Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages","volume":"5","author":"Murray","year":"2010","journal-title":"PloS one"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0535","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1165\/rcmb.2013-0342OC","article-title":"Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model","volume":"50","author":"Murray","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0540","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1378\/chest.94.6.1309","article-title":"Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia","volume":"94","author":"Myers","year":"1988","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.pharmthera.2016.09.010_bb0545","doi-asserted-by":"crossref","first-page":"L1046","DOI":"10.1152\/ajplung.00139.2012","article-title":"Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis","volume":"303","author":"Naik","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0550","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.pharmthera.2016.09.010_bb0555","doi-asserted-by":"crossref","first-page":"33291","DOI":"10.1074\/jbc.M606450200","article-title":"PTEN regulates fibroblast elimination during collagen matrix contraction","volume":"281","author":"Nho","year":"2006","journal-title":"J Biol Chem"},{"issue":"9779","key":"10.1016\/j.pharmthera.2016.09.010_bb0560","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet (Lond Engl)"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0565","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1164\/rccm.201211-2060LE","article-title":"Reply: a placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?","volume":"187","author":"Noth","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0570","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0575","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.09.010_bb0580","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1084\/jem.20101457","article-title":"Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice","volume":"208","author":"Oh","year":"2011","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0585","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00059810","article-title":"Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias","volume":"37","author":"Okamoto","year":"2011","journal-title":"Eur Respir J"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2016.09.010_bb0590","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmthera.2016.09.010_bb0595","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","article-title":"TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis","volume":"192","author":"Oldham","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0600","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1165\/rcmb.2013-0092OC","article-title":"Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules","volume":"50","author":"Olsen","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0605","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1378\/chest.08-0703","article-title":"Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter","volume":"136","author":"Olson","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0610","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3346\/jkms.2009.24.4.614","article-title":"Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function","volume":"24","author":"Park","year":"2009","journal-title":"J Korean Med Sci"},{"issue":"21","key":"10.1016\/j.pharmthera.2016.09.010_bb0615","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1001\/jama.2013.5827","article-title":"Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis","volume":"309","author":"Peljto","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059348","article-title":"Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for \"active\" disease","volume":"8","author":"Peng","year":"2013","journal-title":"PloS one"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0625","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","article-title":"Inhibition of fibrocyte differentiation by serum amyloid P","volume":"171","author":"Pilling","year":"2003","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0630","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.4049\/jimmunol.179.6.4035","article-title":"Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P","volume":"179","author":"Pilling","year":"2007","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0635","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18","volume":"173","author":"Prasse","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0640","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0645","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.09.010_bb0650","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","article-title":"Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial","volume":"178","author":"Raghu","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.09.010_bb0655","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201201-0006PP","article-title":"Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials","volume":"185","author":"Raghu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0660","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0665","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1183\/09031936.06.00037005","article-title":"High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis","volume":"27","author":"Raghu","year":"2006","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0670","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0675","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the antifibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0680","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0685","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1164\/rccm.201101-0058OC","article-title":"Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis","volume":"185","author":"Richards","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0690","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1371\/journal.pmed.0050093","article-title":"MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis","volume":"5","author":"Rosas","year":"2008","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0695","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/ajcn\/31.7.1221","article-title":"Cross-linking amino acids in collagen and elastin","volume":"31","author":"Rucker","year":"1978","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0700","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: the ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0705","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000073718","article-title":"Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro","volume":"132","author":"Saito","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0710","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bbadis.2013.03.001","article-title":"Fibrosis of two: epithelial cell-fibroblast interactions in pulmonary fibrosis","volume":"1832","author":"Sakai","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PloS one"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0720","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.06-2568","article-title":"Molecular targets in pulmonary fibrosis: the myofibroblast in focus","volume":"132","author":"Scotton","year":"2007","journal-title":"Chest"},{"issue":"16","key":"10.1016\/j.pharmthera.2016.09.010_bb0725","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A common MUC5B promoter polymorphism and pulmonary fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N Engl J Med"},{"issue":"7351","key":"10.1016\/j.pharmthera.2016.09.010_bb0730","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10152","article-title":"Latent TGF-beta structure and activation","volume":"474","author":"Shi","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0735","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/thoraxjnl-2012-202403","article-title":"Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial","volume":"68","author":"Shulgina","year":"2013","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0740","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.27382","article-title":"Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis","volume":"62","author":"Sonnylal","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0745","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/ng.3278","article-title":"Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening","volume":"47","author":"Stuart","year":"2015","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0750","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1165\/rcmb.2012-0235ED","article-title":"Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis","volume":"47","author":"Tager","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.09.010_bb0755","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0760","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1164\/rccm.201001-0076OC","article-title":"Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis","volume":"183","author":"Taille","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0765","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2005.10.003","article-title":"Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis","volume":"51","author":"Tang","year":"2006","journal-title":"Lung Cancer (Amsterdam, Neth)"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0770","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1513\/pats.200512-131TK","article-title":"Is idiopathic pulmonary fibrosis an environmental disease?","volume":"3","author":"Taskar","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0775","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1513\/pats.201201-003AW","article-title":"TGF-beta activation and lung fibrosis","volume":"9","author":"Tatler","year":"2012","journal-title":"Proc Am Thorac Soc"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2016.09.010_bb0780","first-page":"S31","article-title":"Reducing affinity of alphavbeta8 interactions with latent TGFbeta: dialling down fibrosis","volume":"3","author":"Tatler","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0785","first-page":"329","article-title":"Lebrikizumab in the personalized management of asthma","volume":"6","author":"Thomson","year":"2012","journal-title":"Biologics"},{"issue":"50","key":"10.1016\/j.pharmthera.2016.09.010_bb0790","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/23\/50\/505101","article-title":"Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice","volume":"23","author":"Trivedi","year":"2012","journal-title":"Nanotechnology"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.09.010_bb0795","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2005.02.052","article-title":"Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2","volume":"43","author":"Vadasz","year":"2005","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.09.010_bb0800","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.200906-0953OC","article-title":"Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort","volume":"182","author":"Van Moorsel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.09.010_bb0805","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1164\/rccm.201309-1592OC","article-title":"C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis","volume":"189","author":"Vuga","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0810","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/ajrccm.150.4.7921434","article-title":"Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia","volume":"150","author":"Walker","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0815","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1524-475X.2007.00292.x","article-title":"Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing","volume":"15","author":"Watterson","year":"2007","journal-title":"Wound Repair Regen"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.09.010_bb0820","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1164\/rccm.2111053","article-title":"Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography","volume":"167","author":"Wells","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0825","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1183\/09031936.95.08020266","article-title":"Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium","volume":"8","author":"Wells","year":"1995","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0830","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00105314","article-title":"Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis","volume":"45","author":"Wilkes","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0835","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/mi.2008.85","article-title":"Pulmonary fibrosis: pathogenesis, etiology and regulation","volume":"2","author":"Wilson","year":"2009","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.09.010_bb0840","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0845","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.09.010_bb0850","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0855","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.ajpath.2013.02.013","article-title":"Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2\/PKC-alpha\/Raf-1\/p44\/42 signaling pathway","volume":"182","author":"Wygrecka","year":"2013","journal-title":"Am J Pathol"},{"issue":"7446","key":"10.1016\/j.pharmthera.2016.09.010_bb0860","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0865","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.ajpath.2014.01.012","article-title":"Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis","volume":"184","author":"Xia","year":"2014","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0870","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.2353\/ajpath.2010.091117","article-title":"Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis","volume":"176","author":"Xia","year":"2010","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.09.010_bb0875","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2353\/ajpath.2009.080160","article-title":"Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q)","volume":"174","author":"Xu","year":"2009","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.09.010_bb0880","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.1203476","article-title":"Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients","volume":"191","author":"Xue","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.pharmthera.2016.09.010_bb0885","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-60327-084-7_7","article-title":"Lysine hydroxylation and cross-linking of collagen","volume":"446","author":"Yamauchi","year":"2008","journal-title":"Methods Mol Biol (Clifton, N.J.)"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.09.010_bb0890","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI5909","article-title":"Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production","volume":"103","author":"Zhu","year":"1999","journal-title":"J Clin Invest"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:27:03Z","timestamp":1749857223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816301668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":178,"alternative-id":["S0163725816301668"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.09.010","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}